CHICAGO – For José Baselga, who took over cancer research and development at AstraZeneca after leaving a top job at Memorial Sloan Kettering under a cloud, new data the company is presenting Sunday morning about using its drug Lynparza in pancreatic cancer are a vindication.

“It’s unbelievable,” said Baselga. “It validates the principle we have been fighting for all these years: that even in the most difficult disease, even the disease where you think you’re not going to win, if you find the genetic vulnerability, if you find that, then those giants, they crumble.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy